National Medical Products Administration seeks opinions: It is proposed that the review and approval of clinical trial applications for innovative drugs meeting the requirements shall be completed within 30 working days.

According to the Securities Times APP, on June 16th, the National Medical Products Administration organized the drafting of the "Notice on Relevant Matters of Optimizing the Review and Approval of Clinical Trials of Innovative Drugs (Draft for Solicitation of Comments)" based on the experience of conducting pilot projects to optimize the review and approval of innovative drug clinical trials. It is now open to the public for comments. It mentioned that in order to further support innovative drug research and development guided by clinical value and improve the quality and efficacy of clinical research and development, the review and approval of clinical trial applications for eligible innovative drugs will be completed within 30 working days. The 30-day channel for drug clinical trial application review and approval supports national key R&D varieties, encourages global early simultaneous R&D and international multicenter clinical trials, and serves clinical needs and the development of the national pharmaceutical industry.